` EVOK (Evoke Pharma Inc) vs S&P 500 Comparison - Alpha Spread

EVOK
vs
S&P 500

Over the past 12 months, EVOK has significantly outperformed S&P 500, delivering a return of +329% compared to the S&P 500's +14% growth.

Stocks Performance
EVOK vs S&P 500

Loading
EVOK
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EVOK vs S&P 500

Performance Gap Between EVOK and GSPC
HIDDEN
Show

Performance By Year
EVOK vs S&P 500

Loading
EVOK
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Evoke Pharma Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Evoke Pharma Inc
Glance View

Market Cap
36.7m USD
Industry
Pharmaceuticals

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

EVOK Intrinsic Value
HIDDEN
Show
Back to Top